[Skip to Content]
[Skip to Content Landing]
Citations 0
Correction
November 28, 2005

Error in Renumbering References in Text and Reference List in: Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study

Arch Intern Med. 2005;165(21):2541. doi:10.1001/archinte.165.21.2541

In the Original Investigation titled “Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study” by Brown et al, published in the May 23rd issue of the ARCHIVES (2005;165:1179-1184), the references were renumbered incorrectly in our publications office before publication. The list is correctly republished herein.

Also on page 1182 in the “Comment” section, paragraph 2, lines 11 to 16 should have read as follows:

“Justman et al8 recently reported a relative risk of incident self-reported DM of 2.0 (95% CI, 1.0- 4.1) when HIV-infected women receiving a PI were compared with an HIV-seronegative subgroup prospectively followed in the Women’s Interagency HIV Study.”

On page 1183, “Comment” section, right hand column, lines 13 to 16 should have read as follows:

“Finally, we did not examine the effect of hepatitis C infection on incident or prevalent DM27; we are investigating this important issue.”

References
1.
Nightingale  SL From the Food and Drug Administration. JAMA 1997;278379PubMedArticle
2.
Carr  ASamaras  KThorisdottir  AKaufmann  GRChisholm  DJCooper  DA Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;3532093- 2099PubMedArticle
3.
Tsiodras  SMantzoros  CHammer  SSamore  M Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;1602050- 2056PubMedArticle
4.
Walli  RGoebel  FDDemant  T Impaired glucose tolerance and protease inhibitors. Ann Intern Med 1998;129837- 838PubMedArticle
5.
Walli  RHerfort  OMichl  GM  et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12F167- F173PubMedArticle
6.
Hadigan  CMeigs  JBCorcoran  C  et al.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32130- 139PubMedArticle
7.
Saves  MRaffi  FCapeau  J  et al.  Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;341396- 1405PubMedArticle
8.
Justman  JEBenning  LDanoff  A  et al.  Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003;32298- 302PubMedArticle
9.
Kaslow  RAOstrow  DGDetels  RPhair  JPPolk  BFRinaldo  CR  Jr The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126310- 318PubMedArticle
10.
 Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;263160- 3167PubMedArticle
11.
Bondar  RJMead  DC Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem 1974;20586- 590PubMed
12.
American Diabetes Association, Clinical practice recommendations 2004. Diabetes Care 2004;271- 150Article
13.
Dybul  MFauci  ASBartlett  JGKaplan  JEPau  AK Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002;137381- 433PubMedArticle
14.
Riddler  SASmit  ECole  SR  et al.  Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;2892978- 2982PubMedArticle
15.
Zou  G A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159702- 706PubMedArticle
16.
Harrell  FERegression Model Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis New York, NY Springer Publishing Co Inc2001;
17.
Cox  DROakes  DAnalysis of Survival Data New York, NY Chapman & Hall1984;
18.
Dever  LLOruwari  PAFigueroa  WEO'Donovan  CAEng  RH Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother 2000;34580- 584PubMedArticle
19.
Murata  HHruz  PWMueckler  M The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;27520251- 20254PubMedArticle
20.
Dufer  MNeye  YKrippeit-Drews  PDrews  G Direct interference of HIV protease inhibitors with pancreatic beta-cell function Naunyn Schmiedebergs Arch Pharmacol 2004;
21.
Lee  GASeneviratne  TNoor  MA  et al.  The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004;18641- 649PubMedArticle
22.
Martinez  EDomingo  PGalindo  MJ  et al.  Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004;381017- 1023PubMedArticle
23.
Lichtenstein  KADelaney  KMArmon  C  et al.  Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;3248- 56PubMedArticle
24.
Mauss  SCorzillius  MWolf  E  et al.  Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002;349- 55PubMedArticle
25.
David  MHHornung  RFichtenbaum  CJ Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 2002;3498- 102PubMedArticle
26.
Wu  SCLi  CYKe  DS The agreement between self-reporting and clinical diagnosis for selected medical conditions among the elderly in Taiwan. Public Health 2000;114137- 142PubMedArticle
27.
Mehta  SHMoore  RDThomas  DLChaisson  RESulkowski  MS The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003;33577- 584PubMedArticle
×